Obesity has grown faster than any other therapy area over the past seven years, at more than 50% a year, and is forecast to lead again to 2033 at around 13%. Metabolic disease sales are on course to rise from around $260 billion in 2022 to roughly $730 billion in 2033. In the latest Evaluate Spotlight episode, Mark Lansdell and I look at what shapes the next phase of the obesity market.
One potentially surprising finding from our analysis is that diabetes remains the larger market, with 56% of metabolic sales in 2033 against 29% for obesity. Tirzepatide and semaglutide sit far above every other molecule, forecast at over $52 billion and close to $25 billion respectively in 2033. Eli Lilly is on course to pass $120 billion in diabetes and obesity sales that year, while Novo Nordisk will just pass $50 billion. Some of this is caused by loss of exclusivity timings. Ozempic and Wegovy lose protection around 2031, while Mounjaro runs to around 2036 and Zepbound to around 2039.
One area we discuss in the webinar is payer coverage, which we’re able to address using data from MMIT. CVS made Wegovy its preferred GLP-1 in July 2025 and moved Zepbound to not covered, then returned Zepbound to covered in October 2026. Many patients pay out of pocket and Medicare offers essentially no coverage, so formulary negotiations feed straight into sales.
There are more than 700 obesity products currently in development, 430 of them preclinical, and it’s interesting to see that dealmaking follows that early-stage pattern. A few highlights from the analysis:
- Close to 80 obesity and diabetes deals were signed over the past two years
- 41 of 75 deals analyzed involved research projects or preclinical assets
- Chinese companies account for 27% of deal volume and 38% of value, against about 16% of volume across all therapy areas in 2025
Efficacy has driven the competition so far but it’s unclear if that will continue to be the case. Further gains offer limited room before weight loss becomes a health concern in its own right, so differentiation is moving to oral formulations, lean-muscle sparing, comorbidity combinations and prevention of weight gain.
The Evaluate Spotlight webinar and report on the metabolic space cover the forecasts, deals, pipeline and late-stage data in detail. Take a look if obesity or diabetes feature in your pipeline or portfolio thinking.